Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
814 Enhancing anti-tumor response in ICI-refractory non-small cell lung cancer through intravenous administration of oncolytic adenovirus armed with hTNFα and hIL-2 in combination with aPD-1 blockade
Compose a Response to This Article
Other responses
No responses have been published for this article.
